Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerry Jurado

Family Medicine Union City, NJ Medical Doctor

NPI 1720004021 CMS profile 260027

2401 Palisade Ave, Union City, NJ 07087

Open in the dashboard

General payments

$43,404

1,696 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jerry Jurado of Union City, NJ is reported in the CMS Open Payments database as having received $43,404 across 1,696 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,772 55
2024 General $7,094 208
2023 General $7,382 300
2022 General $6,754 273
2021 General $7,118 324
2020 General $5,475 293
2019 General $4,809 243

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerry Jurado
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Jerry Jurado were reported at $4,772. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Jerry Jurado Family Medicine median Middle half National median
2019 $4,809 $150 $41–$543 $163
2020 $5,475 $120 $32–$415 $114
2021 $7,118 $137 $35–$551 $132
2022 $6,754 $137 $37–$512 $149
2023 $7,382 $149 $42–$545 $160
2024 $7,094 $156 $44–$560 $164
2025 $4,772 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $6,853 204 payments
  2. Amgen Inc. $3,958 133 payments
  3. Novo Nordisk Inc $3,784 145 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $3,513 90 payments
  5. Janssen Pharmaceuticals, Inc $3,115 137 payments
  6. GlaxoSmithKline, LLC. $2,360 81 payments
  7. Intra-Sana Laboratories $2,350 22 payments
  8. AbbVie, Inc. $1,473 79 payments
  9. Lilly USA, LLC $1,462 91 payments
  10. Ironwood Pharmaceuticals, Inc $1,385 80 payments
  11. Other $13,151 634 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $43,055 1,675 payments
  2. Education $335 20 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $3,014 130 payments
  2. FARXIGA $2,989 96 payments
  3. JARDIANCE $2,419 63 payments
  4. RELTONE 200 MG $2,350 22 payments
  5. GLYCATE $2,350 22 payments
  6. RELTONE 400 MG $2,350 22 payments
  7. Ozempic $2,303 108 payments
  8. BREZTRI $2,207 50 payments
  9. RYBELSUS $1,744 91 payments
  10. Repatha $1,465 83 payments
  11. Other $31,264 1,521 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 153 drugs

Part D claims

14,266

Median for Family Practice: 1,826

Drug cost

$4,284,966

Median for Family Practice: $120,094

Branded share of claims

31.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rybelsus Semaglutide Brand 212 $472,103
Ozempic Semaglutide Brand 304 $432,181
Januvia Sitagliptin Phosphate Brand 298 $370,741
Farxiga Dapagliflozin Propanediol Brand 261 $338,264
Synjardy Xr Empagliflozin/Metformin Hcl Brand 240 $318,077
Jardiance Empagliflozin Brand 239 $309,974
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 216 $274,165
Kerendia Finerenone Brand 85 $133,257
Trulicity Dulaglutide Brand 55 $132,653
Mounjaro Tirzepatide Brand 88 $124,983

The 10 drugs with the highest cost, of 153 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$108,175

Of which drugs: $16,211

Medicare patients

214

Average age 73

Services billed

1,649

130 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Arthritis 38%
Chronic kidney disease 26%
Ischemic heart disease 17%
Osteoporosis 17%
COPD 12%
Cancer 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 33 33 $9,347
Vaccine for influenza for injection into muscle 90662 Office 76 78 $6,231

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$701 — —
JARDIANCE
$622 239 —
BREZTRI
$600 70 —
FARXIGA
$428 261 —
RELTONE 200 MG
$396 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

1,696 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record